biote Corp. (BTMD) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

biote Corp. (BTMD) Healthcare & Pipeline Overview

biote Corp. operates a medical practice-building business within the hormone optimization space, offering a platform for Biote-certified practitioners. The company provides bioidentical hormone therapies, dietary supplements, and sterile pellet insertion kits, distinguishing itself through a focus on hormone imbalance optimization and practitioner support.

What Is the Investment Thesis for BTMD?

biote Corp. presents a focused investment opportunity within the hormone optimization market. With a market capitalization of $63.5M and a P/E ratio of 4.3, the company demonstrates profitability, supported by a gross margin of 70.1% and a profit margin of 8.3%. Key value drivers include the expansion of its network of Biote-certified practitioners and the increasing demand for hormone optimization therapies. Growth catalysts include ongoing marketing efforts and the introduction of new Biote-branded products. Potential risks include competition from other hormone therapy providers and regulatory changes affecting the use of bioidentical hormones. The company's beta of 1.29 indicates higher volatility compared to the market. Investors should monitor the company's ability to maintain its gross margin and expand its practitioner network to sustain growth.

Based on FMP financials and quantitative analysis

BTMD Key Highlights

Market capitalization of $63.5M indicates the company's current valuation in the market.

• P/E ratio of 4.3 suggests the company is potentially undervalued compared to its earnings.
• Gross margin of 70.1% reflects the company's ability to efficiently manage its cost of goods sold.
• Profit margin of 8.3% demonstrates the company's profitability after accounting for all expenses.
• Beta of 1.29 indicates the stock's volatility is higher than the market average.

Who Are BTMD's Competitors?

BTMD is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are BTMD's Key Strengths?

Established platform for hormone optimization.

• Network of Biote-certified practitioners.
• Proprietary Biote-branded products.
• Focus on bioidentical hormone therapies.

What Are BTMD's Weaknesses?

Reliance on Biote-certified practitioners for service delivery.

• Limited geographic reach.
• Potential regulatory risks associated with hormone therapies.
• Competition from other hormone therapy providers.

What Could Drive BTMD Stock Higher?

Introduction of new Biote-branded dietary supplements in Q3 2026, expected to drive revenue growth.

• Expansion of the network of Biote-certified practitioners, increasing the reach of Biote's therapies.
• Marketing campaigns to increase awareness of hormone optimization and Biote's offerings.

What Are the Key Risks for BTMD?

Negative return on equity (-22.9%) — the business is not currently generating profit on shareholder capital.

• Regulatory changes affecting the use of bioidentical hormone therapies could impact the company's business.
• Competition from other hormone therapy providers could erode market share.
• Economic downturn impacting consumer spending on wellness products and services.
• Negative publicity regarding hormone therapies could damage the company's reputation.

What Are the Growth Opportunities for BTMD?

• Expanding the Network of Biote-Certified Practitioners: biote Corp. can increase its revenue by expanding the number of Biote-certified practitioners. The market for hormone optimization is growing, driven by increased awareness of hormone imbalances. By recruiting and training more practitioners, Biote can reach a larger patient base. The company can offer incentives and support to attract new practitioners. This expansion can lead to increased sales of Biote-branded products and therapies. The timeline for this growth opportunity is ongoing, with continuous recruitment and training efforts.
• Introducing New Biote-Branded Products: biote Corp. can develop and launch new Biote-branded products, such as dietary supplements and hormone therapies. The market for dietary supplements is estimated to be worth billions of dollars. By introducing innovative and effective products, Biote can capture a larger share of this market. The company can invest in research and development to create new products. The timeline for this growth opportunity is within the next 1-2 years, with new product launches planned.
• Enhancing the Biote Platform: biote Corp. can improve its platform for Biote-certified practitioners by adding new features and resources. This can include enhanced training programs, marketing support, and patient management tools. By providing a more comprehensive platform, Biote can attract and retain more practitioners. The company can invest in technology and infrastructure to enhance the platform. The timeline for this growth opportunity is ongoing, with continuous improvements and updates planned.
• Expanding into New Geographic Markets: biote Corp. can expand its operations into new geographic markets, both domestically and internationally. The market for hormone optimization is growing globally. By entering new markets, Biote can reach a larger patient base and increase its revenue. The company can conduct market research to identify promising new markets. The timeline for this growth opportunity is within the next 2-3 years, with expansion plans underway.
• Increasing Marketing and Awareness Efforts: biote Corp. can increase its marketing and awareness efforts to educate consumers about the benefits of hormone optimization. This can include online advertising, social media marketing, and partnerships with healthcare providers. By increasing awareness, Biote can drive more patients to Biote-certified practitioners. The company can invest in marketing campaigns and public relations efforts. The timeline for this growth opportunity is ongoing, with continuous marketing efforts planned.

What Are BTMD's Competitive Advantages?

• Established network of Biote-certified practitioners provides a barrier to entry.
• Proprietary platform for hormone optimization offers a unique value proposition.
• Biote-branded products create brand loyalty and recurring revenue.
• Focus on bioidentical hormone therapies differentiates the company from competitors.

What Does BTMD Do?

biote Corp., founded in 2011 and headquartered in Irving, Texas, operates within the burgeoning hormone optimization sector. The company provides a comprehensive platform designed to support medical practitioners in building their practices. This platform enables Biote-certified practitioners to address hormone imbalances in their patients through bioidentical hormone therapies, dietary supplements, and sterile pellet insertion kits. Biote's approach centers on optimizing hormone, vitamin, and mineral levels, offering a holistic approach to patient wellness. The company's product line includes Biote-branded dietary supplements and sterile pellet insertion kits, catering to both men and women. Biote's business model focuses on empowering practitioners with the tools and resources needed to deliver hormone optimization treatments effectively. The company's geographic reach is primarily within the United States, where it continues to expand its network of certified practitioners. Biote differentiates itself through its comprehensive platform, practitioner training, and focus on bioidentical hormone therapies, positioning it as a key player in the hormone optimization market.

What Products and Services Does BTMD Offer?

• Provides a platform for Biote-certified practitioners to offer hormone optimization therapies.
• Offers bioidentical hormone therapies to address hormone imbalances.
• Sells Biote-branded dietary supplements to support overall wellness.
• Provides sterile pellet insertion kits for hormone therapy administration.
• Supports medical practice building for practitioners in the hormone optimization space.
• Offers training and resources for practitioners to become Biote-certified.
• Focuses on optimizing hormone, vitamin, and mineral levels in patients.

How Does BTMD Make Money?

• Generates revenue through the sale of Biote-branded dietary supplements.
• Earns revenue from the sale of sterile pellet insertion kits.
• Collects fees from Biote-certified practitioners for platform access and support.

What Industry Does BTMD Operate In?

biote Corp. operates within the medical care facilities industry, specifically targeting the hormone optimization market. This market is experiencing growth due to increasing awareness of hormone imbalances and the demand for personalized wellness solutions. The competitive landscape includes other hormone therapy providers and wellness clinics. Biote differentiates itself through its focus on bioidentical hormone therapies and its platform for supporting Biote-certified practitioners. The industry is subject to regulatory oversight, which can impact the adoption and use of hormone therapies. Market trends include a growing emphasis on preventative healthcare and personalized medicine.

Who Are BTMD's Key Customers?

• Biote-certified practitioners who use the platform to offer hormone optimization therapies.
• Patients seeking hormone optimization treatments and dietary supplements.
• Medical practices looking to expand their service offerings with hormone therapies.

biote Corp. (BTMD) Valuation Context

Valued at $63.5M, BTMD is classified as a micro-cap stock. Relative to its peer group, BTMD's quantitative score of 67/100 is above the peer average of 54/100.

BTMD Revenue & Earnings Trend

In Q2 2026, BTMD generated $44.2M in top-line revenue, marking a sequential decrease of 1.6%. The company recorded a net loss of $6.6M, with diluted EPS of $-0.23. Revenue has contracted over three consecutive quarters, which investors in this micro-cap Healthcare stock should monitor closely. Across the four most recent quarters, BTMD averaged $0.03 in diluted EPS.

Company Profile

biote Corp. operates in the Medical - Care Facilities industry within the Healthcare sector. It is headquartered in Irving, US. The company is led by CEO Robert C. Peterson. BTMD has traded publicly since 2021.

Return on equity for biote Corp. stands at -22.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 17.5%, showing how much profit it generates from its asset base. BTMD trades at a trailing price-to-earnings ratio of 4.34, below the Healthcare sector average of ~23x. Its free cash flow yield is 29.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.29 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 23.0%, the inverse of the P/E and a quick read on earnings relative to price.

biote Corp.'s Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 2.12 places it in the grey zone, a middle ground that warrants monitoring.

biote Corp. has beaten Wall Street's EPS estimate in 6 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 32.2% below estimates on average.

Wall Street analysts project biote Corp. revenue of about $178.0M for fiscal 2026, with EPS near $0.03. The estimate reflects 3 contributing analysts.

BTMD Financials

BTMD Latest News

BTMD Analyst Consensus

BTMD MoonshotScore

What Investors Ask About biote Corp. (BTMD) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources